FPCP
HEPA

Fort Point Capital Partners’s Hepion Pharmaceuticals HEPA Stock Holding History

Fort Point Capital Partners’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10
Closed -$15K – 291
2021
Q3 		$15K Buy
+10
New +$16K ﹤0.01% 251

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Fort Point Capital Partners's HEPA Position: Q4 2021 in Review

Fort Point Capital Partners sold out of Hepion Pharmaceuticals (HEPA) in Q4 2021, closing a stake of 10 shares — an estimated $15K sold.

Fort Point Capital Partners first reported a position in HEPA in Q3 2021 and held it in 1 quarter. The position peaked at $15K in Q3 2021. 39 funds tracked by Wall St. Rank hold HEPA as of Q4 2021.

  • Fort Point Capital Partners reported no remaining Hepion Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Fort Point Capital Partners sold 10 Hepion Pharmaceuticals shares in Q4 2021, an estimated $15K.
  • Fort Point Capital Partners first reported a position in Hepion Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Fort Point Capital Partners's Hepion Pharmaceuticals position peaked at $15K in Q3 2021.
  • 39 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q4 2021.

Based on Fort Point Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.